Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 29, Issue 10, Pages 505-509Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2008.07.008
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases [1R01 AI063286]
- Juvenile Diabetes Research Foundation
- National Institutes of Health [K01 AR52717-01]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063286] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR052717] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085797] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Protein sumoylation is a post-translational-modification event, in which small ubiquitin-like modifier (SUMO) is covalently attached to protein substrates by a three-step process. Sumoylation has been suggested to regulate multiple cellular processes, including inflammation. Inflammation is initiated in response to pathogenic infections, but uncontrolled inflammatory responses can lead to the development of inflammatory disorders such as rheumatoid arthritis. Recent studies indicate that proinflammatory stimuli, such as tumor necrosis factor a and lipopolysaccharide, can activate PIAS1 [protein inhibitor of activated STAT1 (signal transducer and activator of transcription 1)] SUMO E3 ligase through a SUMO-dependent, inhibitor of kappa 13 kinase alpha (IKK alpha)-mediated phosphorylation event. Activated PIAS1 is then recruited to inflammatory gene promoters to repress transcription. These findings support a hypothesis that therapies targeting the PIAS1 SUMO ligase pathway might be developed for the treatment of inflammatory disorders such as rheumatoid arthritis and atherosclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available